Compare FMS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMS | GH |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | FMS | GH |
|---|---|---|
| Price | $24.07 | $106.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 22 |
| Target Price | $30.00 | ★ $103.82 |
| AVG Volume (30 Days) | 617.1K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $2.15 | $29.73 |
| Revenue Next Year | $2.15 | $27.71 |
| P/E Ratio | $15.62 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $20.96 | $34.91 |
| 52 Week High | $30.46 | $120.74 |
| Indicator | FMS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 49.95 |
| Support Level | $23.82 | $102.00 |
| Resistance Level | $24.71 | $110.46 |
| Average True Range (ATR) | 0.40 | 6.19 |
| MACD | 0.11 | -0.33 |
| Stochastic Oscillator | 71.40 | 46.62 |
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.